Floatz logo

Famitinib

Efficacy

Anhui Provincial HospitalSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Efficacy cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Shandong Provincial Hospital
Phase 4BB
Metformin
Xijing Hospital
Phase 4BB
Pioglitazone
Xijing Hospital
Phase 4B
gv-971
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B
Namenda
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B

View all 37 →

Same molecule, other indications

Famitinib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →